Many fundamental mutations in thyroid cancer target different constituents of the MAPK signaling pathway, including BRAF V600E and RAS gene point mutations, RET::PTC and PAX8::PPARγ chromosomal rearrangements, and telomerase reverse transcriptase (TERT) promoter mutations. This evidence concerns the gene BRAF and thyroid cancer.